Caroline Wilmot
Primary Care · Portland, MENPI 1578085544
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 69.5% of it on its own, with 11 other manufacturers making up the rest.
Across 60 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$632
- Bayer$53
- Boehringer Ingelheim$39
- Corium, LLC$27
- GSK$23
- Scilex Pharmaceuticals Inc.$23
- plus $112 from 6 others
What the payments were for
- Food & beverage$89598%
- Education$142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $632 |
| Bayer | 2 | $53 |
| Boehringer Ingelheim | 2 | $39 |
| Corium, LLC | 2 | $27 |
| GSK | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
$909 in reported general payments places this provider in the 85th percentile of 29 primary care providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $73,122 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $51,917 |
| OzempicSemaglutide | 34 | $50,124 |
| EliquisApixaban | 23 | $31,127 |
| TrulicityDulaglutide | 23 | $29,533 |
| XareltoRivaroxaban | 17 | $25,070 |
| SublocadeBuprenorphine | 11 | $24,158 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 169 | $22,240 |
| RexultiBrexpiprazole | 11 | $16,062 |
| MotegrityPrucalopride Succinate | 17 | $13,897 |
| FarxigaDapagliflozin Propanediol | 17 | $13,862 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $12,987 |
| Xtampza ErOxycodone Myristate | 18 | $11,046 |
| OxycontinOxycodone Hcl | 16 | $9,533 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $39 | $73,12278 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $23 | $62,78289 claims |
| PfizerEliquis | $21 | $31,12723 claims |
| Lilly USA, LLCTrulicity | $16 | $29,53323 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $14 | $24,167216 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $21 | $16,06211 claims |
| AbbVieSynthroid | $632 | $1,49728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 primary care providers in Maine.
Other primary care in Portland
- Rebecca HoldsworthWells$5K
- Renee CourtemancheLewiston$3K
- Kelly DudleyAugusta$2K
- Deanna FelveyAugusta$773
- Shelby StilesMars Hill$558
- Kelsie MilledgeAuburn$517
- Michelle BreenAlbion$473
- Melissa LowerSouthwest Harbor$455
- Regina BlauveltBangor$363
- Molly LobelSpringvale$294
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.